# Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

Source: https://onco.cc/trials/nct06483100/  
OnCo record `nct06483100` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of clonoSEQ in Multiple myeloma, run by Washington University School of Medicine, now recruiting.

## Summary

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance is a phase 2 interventional study registered as NCT06483100 by Washington University School of Medicine, with 65 participants planned, started 2024-12-20 and due to reach its primary completion in 2032-06-30. Interventions recorded: Elrantamab, clonoSEQ. Conditions recorded: Multiple Myeloma.

Linked to the drug clonoSEQ because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06483100
- Phase: 2
- Setting: Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
- Sponsor: Washington University School of Medicine
- Enrolled: 65

## Sources

- ClinicalTrials.gov NCT06483100: https://clinicaltrials.gov/study/NCT06483100

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [clonoSEQ](https://onco.cc/drugs/clonoseq/)

---
JSON: https://onco.cc/api/v1/entities/nct06483100.json